Mineral Wells Index, Mineral Wells, TX

Community News Network

March 5, 2014

Lilly's diabetes drug rejected by FDA

NEW YORK — A diabetes pill developed by Eli Lilly and Boehringer Ingelheim was rejected by U.S. regulators because of previously disclosed manufacturing deficiencies at a German plant that hadn't been resolved.

The Food and Drug Administration inspected Boehringer's Ingelheim am Rhein facility in 2012 and warned the Ingelheim- based company of the faults in May 2013. No new clinical studies will be needed to approved the drug, called empagliflozin, the companies said Wednesday in a statement.

"The complete response letter referenced previously observed deficiencies at a Boehringer Ingelheim facility where empagliflozin will be manufactured," the companies said. The FDA won't approved the drug until the problems are fixed.

About 24 million people in the United States have diabetes, a condition often driven by obesity where the body loses its ability to process sugar.

Empagliflozin is part of a class of drugs that includes Johnson & Johnson's Invokana and AstraZeneca's Forxiga. The drugs help the body get rid of sugar through the kidneys.

The Lilly-Boehringer drug is projected to sell $295 million for Lilly in 2019, according to analyst estimates compiled by Bloomberg.

The FDA re-inspection of Boehringer's plant is continuing, said Emily Baier, a spokeswoman for the company. "The inspection is reviewing aspects related to production, processes, quality assurance and other related areas," said in an email. It could take up to six months after the inspection for the FDA to decide whether the problems have been fixed.

The 2012 inspection found what the FDA called "significant violations of current manufacturing practice" at the plant. They included a failure to look into issues with the active ingredients of drug made there as well as contamination problems that also weren't investigated.

The warning letter last year didn't specifically mention empagliflozin, Philip Johnson, Lilly's vice president of investor relations, said on a Jan. 7 conference call.

"Empagliflozin was not specifically cited in that warning letter," Johnson said. "There was other commercial production that was specifically referenced. Boehringer Ingelheim has been working through this with the FDA."



 

1
Text Only
Community News Network
Featured Ads
Poll

Would you be in favor of or opposed to housing at the closed CCA facility at Wolters Industrial Park some of the unaccompanied children who have crossed illegally into the U.S. and Texas?

In favor
Opposed
Not sure/undecided
Don't care
     View Results
Mineral Wells Index


Click on a photo to visit our SmugMug page

Front page
Weather Underground Radar
Twitter Updates
Follow us on twitter
AP Video
US Ready to Slap New Sanctions on Russia Kerry: Not Worried About Israeli Criticism Boater Rescued From Edge of Kentucky Dam Girl Struck by Plane on Florida Beach Dies Rodents Rampant in Gardens Around Louvre House to Vote on Slimmed-down Bill for Border Looming Demand Could Undercut Flight Safety Raw: 2 Shells Hit Fuel Tank at Gaza Power Plant Raw: Massive Explosions From Airstrikes in Gaza Giant Ketchup Bottle Water Tower Up for Sale Easier Nuclear Construction Promises Fall Short Kerry: Humanitarian Cease-fire Efforts Continue Raw: Corruption Trial Begins for Former Va Gov. The Carbon Trap: US Exports Global Warming Traditional African Dishes Teach Healthy Eating
Must Read
Seasonal Content
Parade
Magazine

Click HERE to read all your Parade favorites including Hollywood Wire, Celebrity interviews and photo galleries, Food recipes and cooking tips, Games and lots more.
Stocks
Hyperlocal Search
Premier Guide
Find a business

Walking Fingers
Maps, Menus, Store hours, Coupons, and more...
Premier Guide